131922-05-9

Basic information

• Product Name: Piperazine, 2-(trifluoromethyl)- (9CI)
• Synonyms: Piperazine, 2-(trifluoromethyl)- (9CI);2-(Trifluoromethyl)piperazine 95%;Piperazine, 2-(trifluoromethyl)-
• CAS NO: 131922-05-9
• Molecular Formula: C₅H₉F₃N₂
• Molecular Weight: 154.1335696
• Product Categories: PIPERIDINE
• Mol File: 131922-05-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 94-97℃
• Boiling Point: 145.1°C at 760 mmHg
• Flash Point: 41.5°C
• Appearance: /
• Density: 1.171g/cm³
• Vapor Pressure: 4.94mmHg at 25°C
• Refractive Index: 1.372
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.75±0.40(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: Piperazine, 2-(trifluoromethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 2-(trifluoromethyl)- (9CI)(131922-05-9)
• EPA Substance Registry System: Piperazine, 2-(trifluoromethyl)- (9CI)(131922-05-9)

Safety Data

• Hazard Codes: C,N
• Statements: 34-50/53
• Safety Statements: 6-26-36/37/39-45-60-61
• RIDADR: UN 3263 8 / PGIII
• WGK Germany: 2
• HazardClass: 8
• Hazardous Substances Data: 131922-05-9(Hazardous Substances Data)

Usage

General Description

Piperazine, 2-(trifluoromethyl)-(9CI), also known as 2-Trifluoromethylpiperazine, is a chemical compound with a variety of potential uses in chemistry and pharmaceuticals. It features a six-membered ring with two nitrogen atoms attached to a trifluoromethyl group, notable for its ability to engage in hydrogen bonding despite the fluorine's high electronegativity. The unique properties of this compound make it a valuable tool for researchers and manufacturers, though like all chemicals, it must be handled properly to ensure safety.

InChI:InChI=1/C5H9F3N2/c6-5(7,8)4-3-9-1-2-10-4/h4,9-10H,1-3H2

Upstream product

• 61655-67-2 2-(trifluoromethyl)pyrazine 
• 431-35-6 3-bromo-1,1,1-trifluoroacetone 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 167566-34-9 1-benzyl-3-(trifluoromethyl)piperazine 

Downstream Products

• 886779-69-7 3-(trifluoromethyl)piperazine-1-carboxylic acid tert-butyl ester 
• 1403897-08-4 1-{6-benzyl-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-c]pyridin-1-yl}-2-[(3R)-3-(fluoromethyl)piperazin-1-yl]ethan-1-one 
• 1403897-05-1 1-{6-benzyl-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-c]pyridin-1-yl}-2-[3-(trifluoromethyl)piperazin-1-yl]ethan-1-one 

Relevant articles and documents

2-(Trifluoromethyl)piperazine: synthesis and characterization using NMR and X-ray photoelectron spectroscopy

The synthesis of 2-(trifluoromethyl)piperazine (1) is reported. 1H NMR spectroscopy shows that in the chair-type piperazine ring the CF3 group occupies an equatorial position.X-ray photoelectron spectroscopy of solid 1 reveals that the CF3 group induces a secondary (β) chemical shift of 1.5 eV on the C 1s core binding energy of its nearest neighbour carbon atom.The results are supported by semi-empirical PM3 and HAM/3 calculations.

5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.

Antiviral indoleoxoacetyl piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.